Paroxysmal Kinesigenic Dyskinesia: First Molecularly Confirmed Case from Africa

  • Marieke C.J. Dekker
  • Rose Chengo
  • Happiness H. Kumburu
  • Erik-Jan Kamsteeg
  • Ben C. Hamel


Background: Paroxysmal kinesigenic dyskinesia (PKD) is a movement disorder, with an excellent response to carbamazepine treatment. It has been described in various populations, but not yet in an African population.

Case report: In a patient who reported to clinic with side effects of carbamazepine, PRRT2 gene screening was performed based on a clinical history compatible with PKD. A common PRRT2 mutation was identified in this patient, hereby the first genetically confirmed PRRT2-associated PKD in Africa.

Discussion: Reporting genetic confirmation of an unusual movement disorder from an equally unusual location shows the wide geographical distribution of PRRT2-associated disease. It also illustrates recognizability of this treatable disorder where the easiest accessible diagnostic tool is neurological history and examination.

Keywords: Paroxysmal Kinesigenic Dyskinesia, Africa, PRRT2, carbamazepine

Citation: Dekker MCJ, Chengo R, Kumburu HH, Kamsteeg E-J, Hamel BC. Paroxysmal kinesigenic dyskinesia: First molecularly confirmed case from Africa. Tremor Other Hyperkinet Mov. 2020; 10. doi: 10.7916/tohm.v0.742